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Fetuin-A, C-reactive protein and LVH in moderate CKD
Abstract. Aims: Left ventricular hyper-
trophy (LVH) is a predictor for cardiovascu-
lar mortality, and it is considered to be a surro-
gate marker of preclinical cardiovascular dis-
ease. This study aimed at evaluating whether
fetuin-A plasma levels are decreased in pa-
tients with moderate chronic kidney disease
(CKD) and their linkage to plasma concentra-
tions of hs-C-reactive protein (CRP), cardio-
trophyn-1 (CT-1), tumor necrosis factor-
(TNF-), propeptide of collagen Type I (PIP)
and to LVH. Material and methods: We
enrolled 64 moderate CKD and 55 essential
hypertensives (EH) with normal renal func-
tion as controls. All the patients underwent an
echocardiographic examination; plasma sam-
ples were obtained to measure routine clinical
parameters and the molecules listed above
(measured by ELISA). Results: Among CKD
there were 30/64 patients with LVH, and in
EH group 14/55 subjects had LVH. Fetuin A
was reduced in CKD when compared with
EH (p < 0.0001). The comparison between
CKD having LVH with those without LVH
showed significant differences in plasma lev-
els of fetuin-A (p < 0.002), TNF- (p < 0.01)
and hs-CRP (p < 0.001), CT-1 and PIP (p <
0.002). CKD with LVH had lower values of
fetuin-A (p < 0.001), and higher values of
hs-CRP (p < 0.001) TNF- (p < 0.001), CT-1
(p < 0.001) and PIP (p < 0.001) than EH with
LVH. The multivariate analysis of correlation
demonstrated that in CKD patients hs-CRP (
0.42, p < 0.00006), and systolic blood pres-
sure ( 0.29, p < 0.02) were independent pre-
dictors of LV mass index. The relationship
between LV mass index and fetuin-A did not
reach statistical significance. Conclusions:
For the first time in moderate CKD patients,
we demonstrate that fetuin-Ais decreased and
relates to LVH depending on C-reactive pro-
tein.
Introduction
Patients with end-stage renal disease as
well as hypertensives with normal renal func-
tion are at high risk for vascular atherosclero-
sis and left ventricular hypertrophy (LVH)
[Chertow et al. 2004, Levy et al. 1990]. In
turn, LVH is an independent predictor for car-
diovascular morbidity and mortality, and it is
considered to be a surrogate marker of pre-
clinical cardiovascular disease [Frohlich et al.
1992, Mancini et al. 2004].
Nevertheless, limited data exist on deter-
minants of LVH in patients in the earliest
stages of CKD [Astor et al. 2004].
Fetuin-A, also called 2 Heremans-Schmid
glycoprotein (AHSG), is a major circulating
protein that is mostly synthesized in the liver
and inhibits calcification by binding hydroxy-
apatite structures. Fetuin-A is ubiquitously
present in the extracellular space at serum con-
centration of 0.5 – 1.0 g/l [Ketteler et al. 2003].
C-reactive protein, a sensitive marker of
inflammation, is thought to represent the state
of chronic low-grade inflammation of the ar-
terial vessel wall at atherosclerotic sites. C-re-
active protein (CRP) predicts consistently
cardiovascular outcome [Blake et al. 2003,
Ross 1999].
Increased amounts of CRP were demon-
strated to be associated with low concentra-
tions of the glycoprotein fetuin-A and with
enhanced cardiovascular and all-cause mor-
tality in uremia [Ketteler et al. 2003]. These
data may account for accelerated athero-
sclerosis.
Tumor necrosis factor- (TNF-) is essen-
tially produced by monocytes and macro-
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phages. It is endowed with the capability of
inducing endothelial activation, and it is the
strongest known paracrine activator of mono-
cytes and macrophages [Deanfield et al.
2005]. Both TNF- and CRP were found in
considerable quantities in atherosclerotic le-
sions [Clausell et al. 1999, Waltenberger et al.
1998], and we demonstrated recently a rela-
tionship between these molecules in essen-
tial-hypertensive patients [Cottone et al.
2006].
TNF- was shown to contribute to the re-
modeling process in the failing myocardium
[Feldman et al. 2000].
Furthermore, it was shown that cardio-
trophyn-1 (CT-1) [Gonzales et al. 2005], a
member of the interleukin-6 superfamily, and
the propeptide of collagen Type I (PIP) in ar-
terial hypertension were increased and asso-
ciated with LVH [Querejeta et al. 2000].
In a cross-sectional study it was demon-
strated that fetuin-A deficiency is associated
with inflammation and links vascular calcifi-
cation to mortality in patients on dialysis
[Ketteler et al. 2003]. Therefore, since LVH is
considered to be a surrogate marker of pre-
clinical cardiovascular disease [Frohlich et al.
1992, Mancini et al. 2004], we hypothesized a
linkage of left ventricular mass (LVM) with
fetuin-A, and either inflammatory or fibrosis
molecules in patients with Stage 3 chronic
kidney disease (CKD).
Therefore, this study was aimed at evalu-
ating whether fetuin-A plasma levels are de-
creased in patients with Stage 3 CKD, that is
GFR 30 – 59 ml/min [K/DOQI 2002], and
whether they are linked to plasma concentra-
tion of high sensitivity CRP, CT-1, TNF-,
PIP and to LVM.
Moderate CKD patients with arterial hy-
pertension were compared with a group of es-
sential hypertensives (EH) matched for age,
blood pressures and duration of hypertensive
disease, and having normal renal function.
Materials and methods
In accordance with the Declaration of
Helsinki and institutional guidelines, the pro-
tocol was approved by the local Ethical Com-
mittee and subjects were aware of the investi-
gational nature of the study and agreed to
participate after informed consent.
Study population
We examined 64 CKD hypertensive pa-
tients entering the program; patients were
moderate CKD [K/DOQI 2002] and were de-
fined hypertensives when clinic systolic/dia-
stolic blood pressure was > 140/90 mmHg, and
severity of hypertension was defined accord-
ing to the Seventh Report of the Joint National
Committee on Detection, Evaluation and
Treatment of High Blood Pressure [Joint Na-
tional Committee on Detection, Evaluation
and Treatment of High Blood Pressure 2003].
Clinic blood pressure was considered as
the average of three consecutive measure-
ments using a mercury sphygmomanometer
after the subject had been sitting for 5 minutes.
55 established hypertensive (EH) sub-
jects, matched for age, body mass index
(BMI), blood pressures and duration of hy-
pertension, and with normal renal function
were enrolled as controls.
In EH secondary and/or complicated forms
of hypertension were ruled out by clinical ex-
amination, determination of serum creatinine,
serum and urinary electrolytes, plasma cate-
cholamine levels and renin activity, renal
echography.
Glomerular filtration rate was estimated
by the Cockroft-Gault formula [Cockroft and
Gault 1976] in all subjects.
Exclusion criteria were age < 30 years and
> 65 years, diabetes mellitus Type 1 or 2 pre-
viously diagnosed, secondary or acceler-
ated-malignant arterial hypertension, history
of either stroke or TIA, and of coronary heart
disease or myocardial infarction, abnormali-
ties of cardiac rhythm or conduction under
pharmacological treatment, cardiac failure.
Due to ethical reasons antihypertensive
medication was not withdrawn. All patients
took the same classes of drugs that were
carvedilol, furosemide and angiotensin re-
ceptor blockers or ACE inhibitors.
Study protocol
On the day of the study, at 9:00 a.m., with
the patients in supine position and after fast-
ing overnight, blood samples were obtained
from an indwelling forearm venous catheter
to assay plasma levels of fetuin-A, CRP, TNF,
CT-1 and PIP.
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All patients underwent echocardiographic
examination to evaluate LVM.
Laboratory methods
Fetuin-A, hs-CRP, TNF-, CT-1, and PIP
were measured by ELISA using a solid-phase
specific sandwich enzyme-linked immuno-
sorbent assay. Standard curves were con-
structed using appropriated concentrations
for each factor. Precautions were taken to
avoid interference with other serum compo-
nents [Deanfield et al. 2005].
Fetuin-A was measured by commercial
kit (Epitope Diagnostics Inc., San Diego, CA,
USA), the sensitivity was 2.5 ng/ml.
High sensitivity CRP was measured by
commercially available ELISA kit (Diagnos-
tic Biochem, London, Canada). The sensitiv-
ity was 10 ng/ml, inter-assay coefficient of
variation was < 10% and the intra-assay coef-
ficient of variation was < 8%.
Tumor necrosis factor- was assayed by
Amersham Biosciences kit (Little Chalfont,
England), sensitivity was < 5 pg/ml, repro-
ducibility of both intra- and between-assay
had a coefficient of variation < 10%.
PIP was analyzed by Takara Bio Inc. com-
mercial kit (Otsu, Japan). The sensitivity was
10 ng/ml, inter-assay coefficient of precision
was  6.3%.
CT-1 was assayed by Biovendor GmbH
commercial kit (Heidelberg, Germany). The
sensitivity was 1 pg/ml, inter-assay coeffi-
cient of variation was 7.8% and the intra-as-
say coefficient of variation was < 9%.
Echocardiography was performed using
an Acuson Sequoia 512 system (Siemens,
Mountain View, CA, USA). Images were
taken in left lateral decubitus position.
Only those frames with optimal visualiza-
tion of interfaces and showing simultaneous
visualization of septum, left ventricular diam-
eters and posterior wall were used for
readings.
Left ventricular mass (LVM) was deter-
mined using the ASE-corrected cube formula
[Devereux et al. 1986] and was indexed by
body surface area (LVMI) and by height ele-
vated by a power of 2.7, as suggested by De
Simone et al. [1992] (LVMH2.7).
Echocardiographic data are expressed as
the average of 5 consecutive cardiac cycles.
Images were read by a single cardiologist,
who was blinded to the patient’s clinical char-
acteristics.
Statistical methods
Differences between groups were evalu-
ated using ANOVA and Student’s t-test. Sim-
ple and multiple regression analyses were
used to test the relationships between the vari-
ables.
The multiple regression analysis was car-
ried out both in the two groups of subjects and
in the group resulting from the association of
CKD with EH patients (n = 119).
These analyses considered LVMI (or
LVMH2.7) as a dependent variable, in a model
comprising age, blood pressures, BMI, lipid
variables, GFR, Hb, PTH, fetuin-A, hs-CRP,
PIP, CT-1, TNF and anti-hypertensive treat-
ment (coded as follows: 0: no treatment, 1:
previous treatment, 2: ACEIs or ARBs, 3: di-
uretics, 4: -blockers, 5: combination of 2 or
more drugs). To avoid the problem of spuri-
ous association deriving from multiple corre-
lations only associations with p < 0.001 were
considered as statistically significant. Results
are given as means ± SD. The null hypothesis
was rejected at a 2-tailed p < 0.05. The statis-
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Table 1. Demographic data of patients with chronic kidney disease (CKD) and
with established hypertension (EH).
CKD (n = 64) EH (n = 55) p <
Age years 57 ± 16 50 ± 12 ns
Male/female 36/28 31/24 ns
Duration hypertension years 5 ± 1 5 ± 0.8 ns
BMI kg/m2 29 ± 4.3 29.5 ± 5 ns
sCr mg/dl 2.8 ± 1.7 0.95 ± 0.13 0.001
GFR ml/min 41 ± 9.84 100.9 ± 9.4 0.001
PTH pg/ml 181 ± 117 38.6 ± 8 0.001
sCa mg/l 9.05 ± 0.37 10.04 ± 0.5 0.001
sP mg/l 4.06 ± 0.99 3.4 ± 0.06 0.001
Hb g/dl 11.3 ± 0.9 14.1 ± 0.04 0.001
SBP mmHg 146 ± 7 146 ± 5.7 ns
DBP mmHg 89 ± 8 90 ± 4 ns
LMV g 267 ± 103 182 ± 25 0.001
LVMI g/m2 127 ± 40 105 ± 25 0.001
LVMH g/m2.7 57 ± 17 50 ± 11 0.01
BMI = body mass index, sCr = serum creatinine, GFR = glomerular filtration rate,
PTH = partiroid hormone, sCa = serum calcium, sP = serum phosphorus, SBP =
systolic blood pressure, DBP = diastolic blood pressure, LVM = left ventricular
mass, LVMI left ventricular mass index, LVMH2.7 = left ventricular mass indexed
by height2.7.
tical analyses were performed using the
SYSTAT DATA software package, version
5.2 (Systat, Evanston, IL, USA).
Results
Table 1 gives demographic data of CKD
and EH patients. The comparison between
hypertensive CKD and hypertensive controls
showed quite similar values of age, BMI,
blood pressures and duration of hypertensive
disease.
Fetuin-A plasma levels were significantly
lower in hypertensive CKD than in EH pa-
tients (Figure 1), this difference was statisti-
cally significant even after adjustment for age
(p = 0.001) and for both age and CRP (p=
0.01). Plasma concentration of hs-CRP as
well as of TNF-, PIP, and CT-1 were higher
in CKD than in EH (Figure 1).
Among CKD there were 30/64 patients
with left ventricular hypertrophy (46.0%),
and in EH group 14/55 (25.5%) subjects had
LVH.
The comparison between moderate CKD
having LVH (n 30) with those without LVH (n
34) showed significant differences in plasma
levels of fetuin-A (p < 0.002), TNF- (p <
0.01) and hs-CRP (p < 0.001), CT-1 and PIP
(p < 0.002) (Table 2). No significant differ-
ences in estimated GFR between the two sub-
groups were observed (44 ± 6.8 vs 40 ± 8.9
ml/min, NS).
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Table 2. Mean levels of plasma concentrations of fetuin-A, Tumor necrosis factor (TNF), high sensitivity
C-reactive Protein (hs-CRP), Cardiotrophin-1 (CT-1) and propeptide of collagen type 1 (PIP) in 64 patients
with chronic kidney disease (CKD) and in 55 established essential hypertensives (EH) with and without left
ventricular hypertrophy (LVH).
Chronic Kidney Disease Essential Hypertension
without LVH with LVH without LVH with LVH
n = 34 n = 30 n = 41 n = 14
Fetuin-A g/l 0.64 ± 0.24# 0.49 ± 0.2°°* 0.96 ± 0.18 0.80 ± 0.2
PIP ng/ml 66 ± 29# 89 ± 40° 47 ± 18 81.7 ± 28
CT-1 pg/ml 63 ± 26# 87 ± 31°°°° 38.5 ± 25 73.4 ± 34
hs-CRP mg/dl 3.28 ± 0.9# 3.91 ± 0.9°°°* 1.9 ± 0.6 2.4 ± 0.5
TNF ng/ml 4.6 ± 0.77# 5 ± 0.95* 3.2 ± 0.5 3.9 ± 0.25
LVMI g/m2 92.5 ± 12 138.8 ± 18°°°° 93 ± 14 143 ± 16
*p < 0.001 CKD vs. EH with LVH, #p < 0.001 CKD vs. EH without LVH, °p < 0.01, °°p < 0.009, °°°p < 0.007,
°°°°p < 0.001 CKD with LVH vs. CKD without LVH, p <0.007, p < 0.0001 EH with LVH vs. EH without
LVH
Figure 1. Mean levels of plasma concentrations of Fetuin-A, Tumor Necrosis Factor (TNF), high sensitivity
C - reactive protein (hs-CRP), Cardiotrophin-1 (CT-1) and propeptide of collagen type I (PIP) in 64 patients
with chronic kidney disease (CKD) and in 55 established essential hypertensives (EH).
On the contrary, we did not observe any
difference among fetuin-A levels when com-
paring EH having and not-having LVH,
whereas significant differences between the
other molecules were found (Table 2).
A further comparison between CKD and
EH patients with LVH demonstrated lower
values of fetuin-A (0.49 ± 0.2 vs 0.80 ± 0.2
g/l, p < 0.001), and higher values of hs-CRP
(3.91 ± 0.9 vs 2.4 ± 0.5 mg/l, p < 0.001),
TNF- (5.25 ± 1.24 vs 3.5 ± 0.51 ng/ml,
p < 0.001), CT-1 (87 ± 31 vs 73.4 ± 34 pg/ml,
p < 0.001) and PIP (89 ± 40 vs 81.7 ± 28 ng/
ml, p < 0.001) in CKD than in EH (Table 2).
Univariate and multivariate
analyses of correlation
In CKD patients the univariate analysis of
correlation demonstrated that fetuin-A was
inversely correlated with serum creatinine
(r –0.70, p < 0.001), plasma phosphorus levels
(r –0.47, p < 0.001), and PTH concentrations
(r –0.557, p < 0.001). Estimated GFR also cor-
related with fetuin-A (r 0.78, p < 0.001).
Furthermore, inverse and significant cor-
relations of fetuin-A with TNF- (r –0.714,
p < 0.001), and hs-CRP (r –0.65, p < 0.001)
plasma levels were found. Interestingly, in
CKD patients fetuin-A correlated negatively
to LVMI (r –0.41, p = 0.001) (Figure 2). In
turn, LVMI showed to be directly correlated
to systolic blood pressure (r 0.43, p = 0.001)
(Figure 3), and to hs-CRP (r 0.58, p < 0.0001)
(Figure 4). On the contrary, in EH controls no
correlation between fetuin-A and LVMI was
found (r –0.07, NS), whereas LVMI was sig-
nificantly correlated to hs-CRP (r 0.44, p <
0.0008). In both groups no significant corre-
lation between fetuin-A and, respectively,
BMI or lipid values was found.
The multiple regression analysis was car-
ried out considering LVMI (or LVMH2.7) as a
dependent variable, in a model comprising
age, blood pressures, BMI, lipid variables,
GFR, Hb, PTH, fetuin-A, hs-CRP, PIP, CT-1,
TNF and anti-hypertensive treatment.
This analysis demonstrated that in CKD
patients hs-CRP ( 0.64, p < 0.004), and sys-
tolic blood pressure ( 0.32, p < 0.006) were
the independent predictors of LVMI. The re-
lationship between LVMI and fetuin-A did
not maintain statistical significance ( –0.27,
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Figure 2. Correlation of Fetuin-A with Left Ventric-
ular Mass Index (LVMI) in moderate chronic kidney
disease patients.
Figure 3. Correlation of Systolic Blood Pressure
(SBP) with Left Ventricular Mass Index (LVMI) in
moderate chronic kidney disease patients.
Figure 4. Correlation of C - reactive protein (CRP)
with Left Ventricular Mass Index (LVMI) in moderate
chronic kidney disease patients.
NS). Similar results were obtained when left
ventricular mass was indexed by height ele-
vated by a power of 2.7, being this latter inde-
pendently associated with hs-CRP ( 0.60,
p < 0.004), systolic blood pressure ( 0.31,
p < 0.006) and BMI ( 0.39, p < 0.0004), but
not with fetuin-A ( –0.26, NS).
The same multiple regression model ap-
plied to the overall study population (n = 119)
confirmed the results observed in the patients
with CKD. In fact, the independent correlates
of LVMI were hs-CRP ( 0.48, p < 0.00001),
and systolic blood pressure ( 0.27, p < 0.001),
and those of LVMH2.7 were hs-CRP ( 0.47,
p < 0.00001), systolic blood pressure ( 0.24,
p < 0.003) and BMI ( 0.26, p < 0.0001).
Discussion
The development of LVH is influenced by
a complex interplay of hemodynamic, neuro-
humoral, genetic and environmental determi-
nants [Frohlich et al. 1992].
LVH is the most common cardiac compli-
cation caused by hypertension, and is a major
risk factor for overall and cardiovascular
mortality in patients with end-stage renal dis-
ease [Levy et al. 1990]. However, limited data
exist on determinants of LVH in patients in
the earliest stages of CKD [Astor et al. 2004],
and to the best of our knowledge, this is the
first report regarding the relationship of left
ventricular mass with hs-CRP and fetuin-A in
patients with moderate CKD.
One most relevant datum of our study is
given by the demonstration of decreased
plasma levels of fetuin-A, associated with in-
creased hs-CRP, and LVMI in moderate CKD
patients in comparison with essential hyper-
tensives having normal renal function, simi-
lar BMI, and matched for blood pressures and
duration of hypertensive disease. We previ-
ously demonstrated that hs-CRP and TNF-
are increased in EH when compared with
healthy normotensive subjects [Cottone et al.
2006], and that in non-uremic CKD plasma
levels of TNF- are higher than in EH
[Cottone et al. 1998, 2002].
In this regard, the results of the present
study are in line with our previous results and
with those by other studies carried out in both
patients not undergoing dialysis and undergo-
ing dialysis [Shlipak et al. 2003, Stam et al.
2003, Wang et al. 2004].
Most noteworthy is the evidence that even
in moderate CKD patients plasma levels of
fetuin-A are significantly decreased, and as-
sociated inversely with both LVM and
hs-CRP. These data are strengthened by the
observation of levels of fetuin-A even lower
in CKD patients having LVH than in those
not-having LVH.
Nonetheless, according to our statistical
analysis, it seems that fetuin-A is not en-
dowed with the property to induce directly
LVH, but it needs CRP activation. Although
fetuin-A was no longer statistically signifi-
cant at entry of CRP into the multivariate re-
gression analysis, its dependence on CRP
suggests a biologically relevant role in the de-
velopment or maintenance of inflammation
and myocardial changes.
Even if similar data were observed in dia-
lyzed patients [Ketteler et al. 2003], this is
just a hypothesis because it is to be estab-
lished whether a statistical analysis mirrors
exactly a biologic phenomenon.
In a cross-sectional study it was demon-
strated that fetuin-A deficiency is associated
with inflammation and links vascular calcifi-
cation to mortality in patients on dialysis
[Ketteler et al. 2003]. Low concentrations of
the glycoprotein were associated with raised
amounts of CRP and with enhanced cardio-
vascular and all-cause mortality. Neverthe-
less, very recently, it has been reported [Ix et
al. 2006] in a cohort of persons with coronary
artery disease and across a broad range of
GFR, that fetuin-A was not inversely associ-
ated with renal function, estimated by four
different methods.
In contrast with the data and the conclu-
sions by Ix et al. [2006], our results seem to
show that both reduction of fetuin-A and its
linkage with CRP and cardiac complication
take place long before the uremic condition
appears.
Actually, between our study and that by Ix et
al. [2006] there are several marked differences.
First of all, our study was aimed at evalu-
ating fetuin-A in patients having LVH, not
coronary calcification, we analyzed GFR
only by one estimation method, and in a
smaller group even considering in the study
by Ix just that subgroup with estimated GFR
more similar to that of our 64 CKD patients.
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Finally, when Ix and colleagues examined
the likelihood of decreased fetuin-A concen-
trations, they found a reduced odds of low
fetuin-Aamong subjects in the higher quartiles
of cystatin-C. These data suggest that the esti-
mation method of GFR could influence the
results.
Based on an experimental study it was hy-
pothesized that in fetuin-A-deficient mice the
severe diastolic dysfunction observed was
ventricular remodeling triggered by a combi-
nation of both cardiac calcification and
fibrosis [Merx et al. 2005].
Serum markers of collagen synthesis or
degradation have been investigated and
found to be altered in hypertension [Gonzales
et al. 2005, Querejeta et al. 2000]. The carb-
oxyterminal propeptide of procollagen Type I
(PIP) correlated with collagen volume frac-
tion on endomyocardial biopsies [Querejeta
et al. 2000].
In our study, PIP was significantly higher
in patients having LVH, both in CKD and EH
groups.
This seems to demonstrate that the in-
creased plasma concentrations of PIP are not
influenced by differences in its clearance.
In our study, the multivariate analyses
confirmed that hs-CRP and systolic blood
pressure are predictors of LVH even in mod-
erate CKD patients.
The relationship between blood pressure
and LVM was clearly established [Verdecchia
et al. 1990]. Less clear are the mechanisms un-
derlying the relationship of CRP with LVH.
In the Cardiovascular Health Study
[Shlipak et al. 2003] renal insufficiency was
independently associated with elevation of
CRP, and Panichi et al. [2002] demonstrated
that CRP rises as renal function declines. On
the contrary, in our study, hs-CRP predicted
LVMI independently of renal function.
One hypothesis could be that blood pres-
sure may modulate the association between in-
flammatory activity, LVH, and renal function.
It is to note that our CKD and EH patients
were matched for blood pressure levels and
duration of hypertensive disease, and they
took the same antihypertensive drugs. In spite
of this, we observed higher hs-CRPlevels and
a greater prevalence of LVH in CKD than in
EH patients.
Because of the established relation of en-
dothelial function and cardiovascular hyper-
trophy [Cottone et al. 1998, Perticone et al.
1999], a second hypothesis could consider the
relationship between CRPand the nitric oxide
pathway [Verma et al. 2002, Zoccali et al.
2000, 2002].
The present study has a few limitations.
First of all, this is a cross-sectional, observa-
tional study. Moreover, the blood concentra-
tions of the molecules we studied could not
exactly reflect the tissue condition. Finally, it
is conceivable that in renal insufficiency a re-
duced clearance of these molecules could
take place, influencing the results.
In conclusion, in a limited fashion with
the findings by our cross-sectional study, we
demonstrate for the first time in moderate
CKD patients that fetuin-A is decreased and
related to left ventricular hypertrophy not di-
rectly, and that its biologic role depends on
C-reactive protein.
This observation could support future
therapeutic choices favoring anti-inflamma-
tory treatment in an early stage of chronic kid-
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